Press Room

Press Release / Feb 21, 2001

Speech delivered by Mr. António Guterres, Prime Minister

on the occasion of his visit to Hovione on 21st February 2001

Speech delivered by Mr. António Guterres, Prime Minister | Hovione

(transcribed and translated at Hovione)

The reason for this visit is very simple:

It was recently decided by both the Government and all social partners, that we would get together to work with well defined objectives, with a view to significatively improving, here in Portugal, both hygiene, safety at work and our fight against accidents, as well as increasing training and qualification of people at work who create prosperity. It is important to say that on signing the agreement relating to hygiene and safety at work, we assumed that, unfortunately, our Country, is lacking in these fields and, in certain sectors, has an accident rate which is intolerable both from a political and moral point of view relative to the people who work and live in Portugal.

It could be thought that these objectives are utopic, but the best way to show that this is not so, is to visit a company that for a long time, and at its own initiative and according to its own strategy, is a centre of excellence. This I take as an example that the Country should know about, not only, but also, in relation to the question of safety. This is the best way to prove to those who do not have this preoccupation sufficiently in mind, what they can and should do and by doing so would not necessarily increase their costs, on the contrary, as has just been mentioned, they could even lower their production costs.

Obviously, safety is not exclusively a worry for firms. The State, as regulator and inspector - must recognize that not having done enough in this field is a worry for the firms – but it is also the responsibility of those who work to behave in a matter that safeguards themselves and others.

We felt that it was very important that the Country should know Hovione because what is done here in this field is absolutely exemplary and can and should, bearing in mind that natural adaptations required according to the different forms of the country’s economic activity, be copied across the Country, showing that the objectives we have set ourselves, on a country wide scale, are perfectly attainable.

Actually, I must refer to another aspect that mentioned here. We have established in our social agreements the right to training. This right, independently from other aspects, assures that all Portuguese workers by 2005 will enjoy 35 hours/year of training. Hovione already offers 70 hours/year training. It is also interesting that training is not something that has been imposed, as a luxury or a political option. In a firm of excellence that assures high standards of technology and is a name in the marketplace, training is an essential component for its own success. At the same time, in this world of constant mutation, it is fundamental to give people the capacity to reply to challenges that are renewed daily as a result of the rapid technological evolution that we live with.

But it would be unjust if I did not take advantage of this occasion to state, in the name of the Government, our great appreciation of what Hovione means to Portugal, and not only in what refers to the questions of safety and training. It is a case of quite exemplary capacity for technological innovation and the proof that when we want to, when we really do everything we can and with enormous determination, the conditions exist in Portugal to do as well as anywhere in the world. However, this is not viable without enormous investment, tremendous dedication, effort and competence.

I know that several decades ago, Eng. Ivan Villax started in a small laboratory in a cellar. From that small laboratory to what we see here today, there are decades of hard work, of competence, of intelligence which, put to work towards an ideal, assured the building of this enterprise. I feel this is an example to be followed as it demonstrates that it is possible, in Portugal, to achieve the best there is in the World and to have things for which we can be proud from every angle. Such as the matters related to technological capacity, innovation, optimization of management, to all those equally important matters of safety and training in social conscience and of belonging to a community. Many firms tend to function isolated from the community without realizing the importance of being part of it.

It is also exemplary that this firm has understood that they can only win by maintaining a constant dialogue with the local community enrichening it at the same time. For all of this, many thanks for this opportunity for the country, more than for myself as I have known of the tradition of excellence that you represent, to grow in self esteem and understand that they too can achieve their own objectives if there is the will and the capacity to do so.

Many thanks.

Also in the Press Room

See All

A mechanical engineering graduate, this Frenchman is the CEO of the Portuguese pharmaceutical contract manufacturer Hovione. Still owned by the founding family, the company was awarded the 2025 ‘Léonardo de Vinci’ Prize, which recognizes the innovative and successful succession planning of family businesses. With an international career behind him, Jean-Luc Herbeaux is almost more fluent in English than in his native language. At 58, this Frenchman with iceberg-blue eyes is the CEO of Hovione. Founded in the late 1950s, this Portuguese group, with 100% family ownership, has just received the ‘Léonardo de Vinci’ Prize, which highlights entrepreneurial successes tinged with family legacy. While this mid-sized company with a turnover of €500 million maintains a low profile, its pharmaceutical contract manufacturing business is just as obscure to the general public. "Yet, the market for contract manufacturers, or 'contract development manufacturing organizations,' is worth $200 billion", emphasizes the CEO, who has been working in this microcosm for two decades. 500 patents Aware of the stakes, he does not deny "the pharma industry's dependence on Indian and Chinese capabilities". "The fact remains that the trend is toward the regionalization of supply chains, with European manufacturers producing for the Old Continent, American manufacturers for their own market, and so on", he says. And to highlight the foresight of Diane and Ivan Villax, the founding couple, "who thought globally from the very beginning". As a result, the group, with its 500 patents, has factories in China, the United States, and Ireland, without neglecting its home territory. This is evident by the site currently under construction on the banks of the Tagus River, following a €200 million investment. "The heavy engineering and compliance aspects are being finalized, "he explains, emphasizing that this highly regulated sector "is under a microscope". He knows this all too well, as Hovione claims to be involved in 5 to 10% of the drugs approved each year by the FDA, the American drug regulatory agency. Professor from Houston to Japan “In this small world, having a good image is important: this is the case with Jean-Luc, passionate about his work, but who knows how to demystify things”, observes Elie Vannier, former chairman of the board of Hovione. He adds that having an international profile is a strength “in this ecosystem where talent and clients are international”. For his part, Jean-Luc retains from his numerous flights “a taste for films of all genres and from all countries”. The son of an administrative employee in secondary schools and an auto insurance expert, the youngest of three children moved around according to his parents' job transfers. He was born in Meaux, grew up in Chartres, and attended the University of Technology of Compiègne, “which already offered programs abroad”. Thus, he left a mechanical engineering internship at a Dior perfume factory to join the University of Houston in Texas, "carrying a 20 kg backpack". Despite his then-limited command of English, he earned a doctorate, became a professor, and met an American woman who would become his wife and the mother of their two children. Next came the University of Kanazawa in Japan. Alas! Disappointed by the academic world, "where you have to fight to get resources", he succumbed to the allure of industry and joined the American chemical company Rohm and Haas, which had fallen under the control of the German company Evonik. 80 million patients He spent twenty years there, in Germany and Singapore, before "accepting the offers from headhunters". He then accepted Hovione's offer, who appointed him Chief Operating Officer in 2020, then CEO two years later, making him the first CEO not from the founding family. The family remains the sole shareholder, which earned the company the ‘Léonardo de Vinci’ Prize, created by the Association Les Hénokiens and the Clos Lucé. Having settled near Lisbon, he substituted walking for combat sports, "having been burned by the injuries of some friends". He also mentioned that Hovione, whose clients include 19 of the world's 20 largest pharmaceutical companies, helps treat more than 80 million patients.   (Translated version)   Read the original and full article in French on LesEchos.fr  

Article

Jean-Luc Herbeaux aims to boost the growth of the pharmaceutical group Hovione

Dec 02, 2025

The CDMO’s New Jersey manufacturing site expansion will eventually cover more than 200,000 square feet. Portugal-based contract development and manufacturing organisation (CDMO) Hovione has completed an initial $100 million investment round in its East Windsor, New Jersey site. Once completed it will increase the facility’s footprint to more than 200,000 square feet and more than double its capacity for spray drying. Hovione CEO Jean-Luc Herbeaux said: “Since launching our New Jersey operations in 2002, Hovione has been one of the longest established European CDMOs in the United States. “This investment reinforces Hovione’s leadership in spray drying – a core technology platform where we have built extensive know-how and capabilities. By continuing to advance our platforms and expand capacity in the US, we are strengthening the foundation that enables our partners to bring complex medicines to patients more efficiently.” Spray drying is an increasingly important particle engineering technology for improving drug bioavailability through the amorphous solid dispersion (ASD) that can address bioavailability or crystallisation challenges. The initial phase of Hovione’s expansion will include a 31,000-square-foot building to house two size-3 spray dryers (PSD-3) designed for ASD production. Construction at the New Jersey site is already underway and the company plans to start GMP operations in the second quarter of 2026. The initiative is part of Hovione’s long-term strategy to grow its US operations and enhance its integrated drug substance, drug product intermediate and drug product capabilities. Herbeaux said: “This investment addresses growing customer demand for US-based capacity and integrated solutions that shorten development timelines and reduce tech transfer complexity. By consolidating development, scale-up, and commercial manufacturing within a single quality and governance framework, we provide customers with seamless execution from drug substance to drug product.” The company’s New Jersey expansion fits into its wider international growth plan that also includes capacity investments in Ireland and Portugal as it seeks to create a network of autonomous sites spanning the development and commercialisation of APIs, drug product intermediates and drug products.   Read the full article at EuropeanPharmaceuticalReview.com  

Press Clipping

Hovione doubles spray drying capacity with $100m US investment round

Nov 04, 2025